Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(10): 948-55
| Autor: | Mauro Carone, Sabina A Antoniu, Italo Sampablo |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Scopolamine Derivatives Pulmonary disease Disease Pulmonary Disease Chronic Obstructive Quality of life Internal medicine Anticholinergic medicine Humans Pharmacology (medical) Tiotropium Bromide Intensive care medicine Survival rate Pharmacology COPD business.industry Mortality rate General Medicine Tiotropium bromide medicine.disease humanities respiratory tract diseases Bronchodilator Agents Respiratory Function Tests Survival Rate Quality of Life business human activities medicine.drug |
| Zdroj: | Expert opinion on pharmacotherapy. 11(8) |
| ISSN: | 1744-7666 |
| Popis: | Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality.Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality.What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well.Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|